References
- Wilson C. G., Palmer A. W., Zuo F., Eugui E., Wilson S., Mackenzie R., et al. Selective and non‐selective metalloproteinase inhibitors reduce IL‐1‐induced cartilage degradation and loss of mechanical properties. Matrix Biol 2007; 26: 259–68
- Johnson A. R., Pavlovsky A. G., Ortwine D. F., Prior F., Man C. F., Bornemeier D. A., et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease‐13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007; 282: 27781–91
- Schaller S., Henriksen K., Hoegh‐Andersen P., Sondergaard B. C., Sumer E. U., Tanko L. B., et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?. Assay Drug Dev Technol 2005; 3: 553–80
- Karsdal M. A., Sumer E. U., Wulf H., Madsen S. H., Christiansen C., Fosang A. J., et al. Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase‐mediated cartilage degradation, but not aggrecanase‐mediated cartilage degradation. Arthritis Rheum 2007; 56: 1549–58
- Beekman B., Verzijl N., Bank R. A., von der Mark K., TeKoppele J. M. Synthesis of collagen by bovine chondrocytes cultured in alginate: posttranslational modifications and cell–matrix interaction. Exp Cell Res 1997; 237: 135–41
- Castagnola P., Dozin B., Moro G., Cancedda R. Changes in the expression of collagen genes show two stages in chondrocyte differentiation in vitro. J Cell Biol 1988; 106: 461–7
- Sondergaard B. C., Wulf H., Henriksen K., Schaller S., Oestergaard S., Qvist P., et al. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage 2006; 14: 759–68
- Olsen A. K., Sondergaard B. C., Byrjalsen I., Tanko L. B., Christiansen C., Muller A., et al. Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 2007; 15: 335–42
- Tyler J. A. Insulin‐like growth factor 1 can decrease degradation and promote synthesis of proteoglycan in cartilage exposed to cytokines. Biochem J 1989; 260: 543–8
- Goldring M. B. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Pract Res Clin Rheumatol 2006; 20: 1003–25
- Fukui N., McAlinden A., Zhu Y., Crouch E., Broekelmann T. J., Mecham R. P., et al. Processing of type II procollagen amino propeptide by matrix metalloproteinases. J Biol Chem 2002; 277: 2193–201
- Al‐Nasiry S., Geusens N., Hanssens M., Luyten C., Pijnenborg R. The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells. Hum Reprod 2007; 22: 1304–9
- Farndale R. W., Sayers C. A., Barrett A. J. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res 1982; 9: 247–8
- Behrens F., Kraft E. L., Oegema T. R., Jr. Biochemical changes in articular cartilage after joint immobilization by casting or external fixation. J Orthop Res 1989; 7: 335–43